The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity

Sarah L. Tan; Tessa Potezny; Jordan Y. Li

doi:10.1111/nep.13950

The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity

Sarah L. Tan
, Tessa Potezny
, Jordan Y. Li

College of Medicine and Public Health

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Crescentic IgA nephropathy (IgAN) with concurrent myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) is rare. It may represent a subgroup of IgAN with a different response to standard treatment.

Original language	English
Pages (from-to)	216-217
Number of pages	2
Journal	Nephrology
Volume	27
Issue number	2
DOIs	https://doi.org/10.1111/nep.13950
Publication status	Published - Feb 2022

Keywords

crescentic IgA nephropathy
ANCA-positive vasculitis
rituximab
MPO-ANCA
cyclophosphamide

Access to Document

10.1111/nep.13950Licence: In Copyright

Cite this

@article{7fbcde7276b844058b8a43717f7d9489,

title = "The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity",

abstract = "Crescentic IgA nephropathy (IgAN) with concurrent myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) is rare. It may represent a subgroup of IgAN with a different response to standard treatment.",

keywords = "crescentic IgA nephropathy, ANCA-positive vasculitis, rituximab, MPO-ANCA, cyclophosphamide",

author = "Tan, \{Sarah L.\} and Tessa Potezny and Li, \{Jordan Y.\}",

year = "2022",

month = feb,

doi = "10.1111/nep.13950",

language = "English",

volume = "27",

pages = "216--217",

journal = "Nephrology",

issn = "1320-5358",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity

AU - Tan, Sarah L.

AU - Potezny, Tessa

AU - Li, Jordan Y.

PY - 2022/2

Y1 - 2022/2

N2 - Crescentic IgA nephropathy (IgAN) with concurrent myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) is rare. It may represent a subgroup of IgAN with a different response to standard treatment.

AB - Crescentic IgA nephropathy (IgAN) with concurrent myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) is rare. It may represent a subgroup of IgAN with a different response to standard treatment.

KW - crescentic IgA nephropathy

KW - ANCA-positive vasculitis

KW - rituximab

KW - MPO-ANCA

KW - cyclophosphamide

UR - https://www.scopus.com/pages/publications/85111356168

U2 - 10.1111/nep.13950

DO - 10.1111/nep.13950

M3 - Letter

C2 - 34322932

AN - SCOPUS:85111356168

SN - 1320-5358

VL - 27

SP - 216

EP - 217

JO - Nephrology

JF - Nephrology

IS - 2

ER -

The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this